Published in Am J Pathol on December 01, 2002
Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma | NCT00868192
Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol (2004) 3.47
Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One (2010) 3.38
Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res (2013) 3.27
Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res (2008) 1.92
Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. Neoplasia (2011) 1.56
Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med (2014) 1.55
Inhibition of PKCδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancer. J Clin Invest (2011) 1.35
Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer Metastasis Rev (2012) 1.31
Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis. Am J Pathol (2005) 1.22
Angiogenesis in platelet endothelial cell adhesion molecule-1-null mice. Am J Pathol (2009) 1.18
Involvement of endothelial CD44 during in vivo angiogenesis. Am J Pathol (2006) 1.14
F3-targeted cisplatin-hydrogel nanoparticles as an effective therapeutic that targets both murine and human ovarian tumor endothelial cells in vivo. Cancer Res (2010) 1.09
Development of a syngeneic mouse model of epithelial ovarian cancer. J Ovarian Res (2010) 1.06
Xenograft and Transgenic Mouse Models of Epithelial Ovarian Cancer and Non Invasive Imaging Modalities to Monitor Ovarian Tumor Growth In situ -Applications in Evaluating Novel Therapeutic Agents. Curr Protoc Pharmacol (2009) 1.06
Endothelin receptor-A is required for the recruitment of antitumor T cells and modulates chemotherapy induction of cancer stem cells. Cancer Biol Ther (2012) 1.04
A homeobox gene related to Drosophila distal-less promotes ovarian tumorigenicity by inducing expression of vascular endothelial growth factor and fibroblast growth factor-2. Am J Pathol (2007) 1.03
Whole tumor antigen vaccination using dendritic cells: comparison of RNA electroporation and pulsing with UV-irradiated tumor cells. J Transl Med (2008) 1.00
A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer. J Transl Med (2013) 0.99
Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer. Clin Cancer Res (2010) 0.99
Cellular and molecular processes in ovarian cancer metastasis. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis. Am J Physiol Cell Physiol (2015) 0.97
Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy. J Transl Med (2011) 0.96
Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18. J Transl Med (2009) 0.96
In vivo dendritic cell tracking using fluorescence lifetime imaging and near-infrared-emissive polymersomes. Mol Imaging Biol (2009) 0.96
Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary. Mol Cancer Ther (2010) 0.95
Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies. Gynecol Oncol (2007) 0.93
Generation and characterization of an ascitogenic mesothelin-expressing tumor model. Cancer (2007) 0.93
Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer. J Transl Med (2008) 0.90
Effects of nerve growth factor (NGF) on blood vessels area and expression of the angiogenic factors VEGF and TGFbeta1 in the rat ovary. Reprod Biol Endocrinol (2006) 0.88
Transcriptional regulation of PIK3CA oncogene by NF-kappaB in ovarian cancer microenvironment. PLoS One (2008) 0.88
Downregulation of developmentally regulated endothelial cell locus-1 inhibits the growth of colon cancer. J Biomed Sci (2008) 0.86
Suppression of epithelial ovarian cancer invasion into the omentum by 1α,25-dihydroxyvitamin D3 and its receptor. J Steroid Biochem Mol Biol (2014) 0.85
T cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression. Cancer Immunol Res (2014) 0.85
The interplay between surfaces and soluble factors define the immunologic and angiogenic properties of myeloid dendritic cells. BMC Immunol (2011) 0.85
A novel regulation of VEGF expression by HIF-1α and STAT3 in HDM2 transfected prostate cancer cells. J Cell Mol Med (2012) 0.84
Differential roles of uPAR in peritoneal ovarian carcinomatosis. Neoplasia (2012) 0.78
Attenuated Toxoplasma gondii Stimulates Immunity to Pancreatic Cancer by Manipulation of Myeloid Cell Populations. Cancer Immunol Res (2015) 0.78
Adhesion to substrates induces dendritic cell endothelization and decreases immunological response. Immunobiology (2012) 0.77
An immunocompetent, orthotopic mouse model of epithelial ovarian cancer utilizing tissue engineered tumor cell sheets. Tissue Eng Part C Methods (2015) 0.77
Migration-inducing gene 7 promotes tumorigenesis and angiogenesis and independently predicts poor prognosis of epithelial ovarian cancer. Oncotarget (2016) 0.75
The hallmarks of cancer. Cell (2000) 113.05
Angiogenesis in cancer and other diseases. Nature (2000) 28.28
Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci U S A (1993) 22.33
An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods (1999) 17.06
Vascular-specific growth factors and blood vessel formation. Nature (2000) 14.42
Cancer statistics, 2001. CA Cancer J Clin (2001) 11.73
Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell (1998) 10.32
The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science (1992) 7.49
Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol (1989) 7.47
Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med (1996) 6.11
Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun (1992) 5.31
Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev (2000) 5.16
The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell (1993) 4.33
VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature (2002) 4.10
Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis (2000) 4.06
Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol (2001) 3.84
Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J Clin Invest (2002) 3.70
The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci (2001) 3.54
Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res (2000) 3.47
Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Annu Rev Immunol (1996) 2.96
Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res (2001) 2.85
The mouse gene for vascular endothelial growth factor. Genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences. J Biol Chem (1996) 2.58
Differential expression of VEGF isoforms in mouse during development and in the adult. Dev Dyn (2001) 2.53
Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res (1999) 2.49
Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol (2002) 2.46
Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst (1995) 2.44
Activation of the HIF pathway in cancer. Curr Opin Genet Dev (2001) 2.38
Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood (2001) 2.27
Neuropilin-2 is a receptor for the vascular endothelial growth factor (VEGF) forms VEGF-145 and VEGF-165 [corrected]. J Biol Chem (2000) 2.25
Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer (1999) 2.17
Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest (2000) 2.08
Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res (1999) 2.05
Isoforms of vascular endothelial growth factor act in a coordinate fashion To recruit and expand tumor vasculature. Mol Cell Biol (2000) 1.95
Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci U S A (2001) 1.90
Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol (1998) 1.90
Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in human neuroblastomas. Med Pediatr Oncol (2000) 1.66
Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist (2000) 1.61
Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer (2000) 1.51
Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer (2000) 1.30
Vascular endothelial growth factor: acting as an autocrine growth factor for human gastric adenocarcinoma cell MGC803. Biochem Biophys Res Commun (2001) 1.27
Orthotopic transplant mouse models with green fluorescent protein-expressing cancer cells to visualize metastasis and angiogenesis. Cancer Metastasis Rev (1999) 1.18
Vascular endothelial growth factor inhibits apoptotic death in hematopoietic cells after exposure to chemotherapeutic drugs by inducing MCL1 acting as an antiapoptotic factor. Cancer Res (1998) 1.17
Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma. Eur J Cancer (1999) 1.16
Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Lett (1997) 1.13
The enhanced green fluorescent protein (eGFP) is minimally immunogenic in C57BL/6 mice. Gene Ther (2001) 1.11
Expression and functional significance of vascular endothelial growth factor receptors in human tumor cells. Lab Invest (1999) 1.11
Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model. Clin Cancer Res (1999) 1.11
Different effects of glucose starvation on expression and stability of VEGF mRNA isoforms in murine ovarian cancer cells. Biochem Biophys Res Commun (2002) 1.10
Secretion of vascular endothelial growth factor in ovarian cancer. Eur J Gynaecol Oncol (1999) 1.08
TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Clin Cancer Res (2003) 1.07
Molecular regulation of angiogenesis in the skin. J Invest Dermatol (1996) 1.06
Production of VEGF and expression of the VEGF receptors Flt-1 and KDR in primary cultures of epithelial and stromal cells derived from breast tumours. Br J Cancer (1999) 1.06
Detection of a decrease in green fluorescent protein fluorescence for the monitoring of cell death: an assay amenable to high-throughput screening technologies. Cytometry (2001) 1.05
Vascular endothelial growth factor isoform expression as a determinant of blood vessel patterning in human melanoma xenografts. Cancer Res (2002) 1.05
p73 Overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumor angiogenesis. Oncogene (2001) 1.02
Tumor angiogenesis factors reduce leukocyte adhesion in vivo. Int Immunol (2000) 0.98
Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF. Biochem Biophys Res Commun (1995) 0.98
Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival. Gynecol Oncol (1999) 0.97
Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage. Gynecol Oncol (2002) 0.95
Angiogenesis in malignancies of the female genital tract. Gynecol Oncol (1999) 0.94
Chemotherapy resistance in ovarian cancer: new molecular perspectives. Obstet Gynecol (1998) 0.93
Visualization of GFP-expressing tumors and metastasis in vivo. Biotechniques (2001) 0.92
Regulation of the acute myeloid leukemia cell line OCI/AML-2 by endothelial nitric oxide synthase under the control of a vascular endothelial growth factor signaling system. Leukemia (2001) 0.92
Vascular endothelial growth factor-165 overexpression stimulates angiogenesis and induces cyst formation and macrophage infiltration in human ovarian cancer xenografts. Am J Pathol (2002) 0.88
Prognostic significance of microvessel density, vascular cuffing and vascular endothelial growth factor expression in ovarian carcinoma: a special review for clear cell adenocarcinoma. Cancer Lett (2002) 0.87
Tumor growth enhancing effects of vascular endothelial growth factor are associated with increased nitric oxide synthase activity and inhibition of apoptosis in human breast carcinoma xenografts. Cancer Lett (2002) 0.85
Microvascular permeability of human melanoma xenografts to macromolecules: relationships to tumor volumetric growth rate, tumor angiogenesis, and VEGF expression. Microvasc Res (2001) 0.85
Angiogenesis in ovarian cancer: molecular pathology and therapeutic strategies. Curr Oncol Rep (2002) 0.84
Vascular endothelial growth factor in ovarian cyst fluid. Cancer (2001) 0.84
Prognostic value of angiogenesis in gastro-intestinal tumours. Eur J Cancer (1996) 0.83
Prognostic factors in stage I/II non-small cell lung cancer. Lung Cancer (2001) 0.80
In vitro analysis of transformation potential associated with retroviral vector insertions. Hum Gene Ther (1999) 0.79
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med (2003) 16.62
Cancer immunotherapy comes of age. Nature (2011) 12.35
microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A (2006) 8.24
The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol (2008) 7.86
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood (2009) 4.80
Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A (2008) 4.79
Modulation of the antitumor immune response by complement. Nat Immunol (2008) 4.53
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature (2011) 4.07
miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther (2007) 3.93
Laser-capture microdissection. Nat Protoc (2006) 3.80
Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med (2004) 3.55
Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol (2002) 3.43
Vaginal cuff recurrence of endometrial cancer treated by laparoscopic-assisted vaginal hysterectomy. Gynecol Oncol (2003) 3.39
Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One (2010) 3.38
Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med (2008) 3.35
Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res (2013) 3.27
Mastermind critically regulates Notch-mediated lymphoid cell fate decisions. Blood (2004) 2.90
Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol (2011) 2.67
Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol (2007) 2.63
T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res (2012) 2.43
A mouse model of human L1 retrotransposition. Nat Genet (2002) 2.39
MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res (2008) 2.35
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Mechanisms of microRNA deregulation in human cancer. Cell Cycle (2008) 2.30
Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res (2007) 2.25
Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. J Clin Oncol (2004) 2.24
Deciphering and reversing tumor immune suppression. Immunity (2013) 2.24
Transcription factor EBF restricts alternative lineage options and promotes B cell fate commitment independently of Pax5. Nat Immunol (2008) 2.19
The decline in B lymphopoiesis in aged mice reflects loss of very early B-lineage precursors. J Immunol (2003) 2.17
Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med (2004) 2.06
Vascular leukocytes contribute to tumor vascularization. Blood (2004) 2.03
Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res (2007) 2.01
KLF17 is a negative regulator of epithelial-mesenchymal transition and metastasis in breast cancer. Nat Cell Biol (2009) 1.97
Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of B-cell malignancies. Blood (2005) 1.96
Characterization of marginal zone B cell precursors. J Exp Med (2005) 1.92
Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res (2008) 1.92
Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol (2008) 1.90
CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin Cancer Res (2013) 1.90
The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev Immunol (2011) 1.82
Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res (2013) 1.78
Double-negative feedback loop between reprogramming factor LIN28 and microRNA let-7 regulates aldehyde dehydrogenase 1-positive cancer stem cells. Cancer Res (2010) 1.78
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77
Cancer and inflammation: promise for biologic therapy. J Immunother (2010) 1.72
Integrative genomic analysis of protein kinase C (PKC) family identifies PKCiota as a biomarker and potential oncogene in ovarian carcinoma. Cancer Res (2006) 1.70
In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res (2011) 1.62
Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res (2003) 1.62
Generation of peripheral B cells occurs via two spatially and temporally distinct pathways. Blood (2006) 1.61
The earliest step in B lineage differentiation from common lymphoid progenitors is critically dependent upon interleukin 7. J Exp Med (2002) 1.61
Deltex1 redirects lymphoid progenitors to the B cell lineage by antagonizing Notch1. Immunity (2002) 1.55
Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol (2007) 1.55
B lineage-specific regulation of V(D)J recombinase activity is established in common lymphoid progenitors. J Exp Med (2004) 1.53
Integrative genomic analysis of phosphatidylinositol 3'-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer. Clin Cancer Res (2007) 1.48
Oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors following spontaneous silencing/reactivation of the EBF/Pax5 pathway. Blood (2002) 1.48
Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol (2005) 1.45
Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics (2003) 1.40
Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk. J Natl Cancer Inst (2006) 1.39
Identification of microRNAs regulating reprogramming factor LIN28 in embryonic stem cells and cancer cells. J Biol Chem (2010) 1.38
Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology (2013) 1.37
Transcriptional coactivator Drosophila eyes absent homologue 2 is up-regulated in epithelial ovarian cancer and promotes tumor growth. Cancer Res (2005) 1.37
Cancer cell lines as genetic models of their parent histology: analyses based on array comparative genomic hybridization. Cancer Res (2007) 1.36
Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor. Mol Ther (2011) 1.35
Primary lymphomas of the cervix and uterus: the University of Pennsylvania's experience and a review of the literature. Leuk Lymphoma (2006) 1.35
Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. Cancer (2009) 1.32
HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer. Mol Ther (2005) 1.28
Visualizing PU.1 activity during hematopoiesis. Exp Hematol (2005) 1.28
Wnt5a is expressed in murine and human atherosclerotic lesions. Am J Physiol Heart Circ Physiol (2008) 1.28
Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors--response. Cancer Res (2014) 1.28
Case-control study of postmenopausal hormone replacement therapy and endometrial cancer. Am J Epidemiol (2006) 1.27
Workshop on cancer biometrics: identifying biomarkers and surrogates of cancer in patients: a meeting held at the Masur Auditorium, National Institutes of Health. J Immunother (2005) 1.25
Differential requirement for LAT and SLP-76 in GPVI versus T cell receptor signaling. J Exp Med (2002) 1.24
Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines. Front Biosci (Landmark Ed) (2009) 1.23
Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol (2011) 1.23
MicroRNA epigenetic alterations in human cancer: one step forward in diagnosis and treatment. Int J Cancer (2008) 1.21
Regulation of peripheral B cell maturation. Cell Immunol (2006) 1.21
Whole tumor antigen vaccines. Semin Immunol (2010) 1.19
A phase II trial of intraperitoneal photodynamic therapy for patients with peritoneal carcinomatosis and sarcomatosis. Clin Cancer Res (2006) 1.19
Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome. Genes Chromosomes Cancer (2011) 1.18
Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol (2014) 1.18
Immunotherapy opportunities in ovarian cancer. Expert Rev Anticancer Ther (2008) 1.18
Immunotherapy for ovarian cancer: what's next? J Clin Oncol (2010) 1.17
Predicting time to ovarian carcinoma recurrence using protein markers. J Clin Invest (2013) 1.17
Involvement of endothelial CD44 during in vivo angiogenesis. Am J Pathol (2006) 1.14
A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol (2009) 1.14